Biocon Ltd reported a 57.3 per cent decline in consolidated net profit to Rs 56.7 crore for the September quarter of FY27, primarily due to a USD 20 million revenue recognition delay caused by geopolitical troubles, which is now expected to be booked in the third quarter.
Biocon is actively seeking in-licensing opportunities to expand its biosimilars portfolio, focusing on products that complement existing therapy areas, as the company shifts to a 'consolidate' phase with a strong emphasis on improving capacity utilisation, expanding margins, and driving return on capital employed.
'We recently launched Yesintek in the immunology space.'